Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1983 2
1984 1
1985 1
1987 2
1988 5
1989 1
1990 2
1991 2
1993 1
1994 2
1995 9
1996 8
1997 5
1998 5
1999 5
2000 4
2001 10
2002 7
2003 12
2004 9
2005 12
2006 14
2007 8
2008 14
2009 13
2010 6
2011 5
2012 10
2013 8
2014 10
2015 8
2016 6
2017 8
2018 4
2019 6
2020 1
2021 9
2022 16
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Rodda S, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6. Int J Radiat Oncol Biol Phys. 2017. PMID: 28433432 Clinical Trial.
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Morris WJ, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24. Int J Radiat Oncol Biol Phys. 2017. PMID: 28262473 Clinical Trial.
An Updated Analysis of the Survival Endpoints of ASCENDE-RT.
Oh J, Tyldesley S, Pai H, McKenzie M, Halperin R, Duncan G, Morton G, Keyes M, Hamm J, Morris WJ. Oh J, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1061-1070. doi: 10.1016/j.ijrobp.2022.11.005. Epub 2022 Dec 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 36528488 Clinical Trial.
Improved methods for RNAseq-based alternative splicing analysis.
Halperin RF, Hegde A, Lang JD, Raupach EA; C4RCD Research Group; Legendre C, Liang WS, LoRusso PM, Sekulic A, Sosman JA, Trent JM, Rangasamy S, Pirrotte P, Schork NJ. Halperin RF, et al. Sci Rep. 2021 May 24;11(1):10740. doi: 10.1038/s41598-021-89938-2. Sci Rep. 2021. PMID: 34031440 Free PMC article.
Germline CDKN1B variant type and site are associated with phenotype in MEN4.
Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A, Friedman E, Bernstein-Molho R, Tirosh A. Halperin R, et al. Endocr Relat Cancer. 2022 Dec 12;30(1):e220174. doi: 10.1530/ERC-22-0174. Print 2023 Jan 1. Endocr Relat Cancer. 2022. PMID: 36256846 Review.
The Practice of Radiation Oncology in Canada.
Lalani N, Cummings B, Halperin R, Rakovitch E, Brundage M, Vigneault E, Milosevic M. Lalani N, et al. Among authors: halperin r. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):876-880. doi: 10.1016/j.ijrobp.2016.11.055. Epub 2016 Dec 14. Int J Radiat Oncol Biol Phys. 2017. PMID: 28333001 No abstract available.
Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.
Anker J, Pal SK, Kim-Schulze S, Wang H, Halperin R, Uzilov A, Imai N, Eikawa S, Saito T, Sebra R, Hahn NM, Patel M, Qi J, Xie H, Bhardwaj N, Gnjatic S, Galsky MD. Anker J, et al. Among authors: halperin r. J Immunother Cancer. 2023 Aug;11(8):e007613. doi: 10.1136/jitc-2023-007613. J Immunother Cancer. 2023. PMID: 37607770 Free PMC article.
235 results